EXPERIMENTAL AND CLINICAL STUDIES OF CEFSULODIN (SCE-129) IN PATIENTS WITH <I>PSEUDO MONAS</I> INFECTIONS OF URINARY TRACT

DOI Web Site

Bibliographic Information

Other Title
  • 緑膿菌による複雑性尿路感染症に対するCefsulodin (SCE-129) の基礎的, 臨床的検討
  • リョクノウキン ニヨル フクザツセイ ニョウロ カンセンショウ ニ タイスル

Search this article

Abstract

Cefsulodin (SCE-129, CFS), a new cephalosporin derivative synthesized in Japan, was evaluated experimentally and clinically. The results obtained were as follows:<BR>1) Minimal inhibitory concentrations of CFS, sulbenicillin (SBPC) and gentamicin (GM) were determined against 18 clinical isolates of Pseudomonas aeruginosa. CFS was more active than SBPC or GM.<BR>2) CFS was administered intramuscularly at a single dose of 250 mg to 2 male healthy volunteers and 6 patients with normal or impaired renal function. The serum and urinary concentrations were assayed by cup method during 6 hours after administration. The serum concentrations showed peak at 1 hour after injection in all cases. The half-life of CFS was calculated for 1.3 hours in the volunteers, and became prolonged as the renal function fell.<BR>Seventy-six per cent of administered dose was excreted in the urine during the first 6 hours of administration.<BR>3) Twelve patients with Pseudomonas infection of urinary tract were given CFS intramuscularly in daily dose of 500 mg twice a day for 7 days. The clinical results obtained were excellent in 2 cases (16 7%), good in 1 case (8.3%) and poor in 9 cases (75.0%).<BR>4) No marked side effects were observed.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 27 (Supplement2), 317-324, 1979

    Japanese Society of Chemotherapy

Details 詳細情報について

Report a problem

Back to top